Digital Sponsored Webinar wrap-up: How pharma can leverage AI-driven synthetic... Synthetic personas turn static, traditional personas into interactive, evidence-backed simulations.
Views & Analysis The patient segmentation model Dividing patients into groups based on how they behave towards their condition aids understanding.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.